STAINES-UPON-THAMES, United
Kingdom, Oct. 9, 2019
/PRNewswire/ -- Mallinckrodt
plc (NYSE: MNK), a global biopharmaceutical company, announced
today that it will report third quarter 2019 earnings results for
the period ended Sept. 27, 2019 on
Tuesday, Nov. 5, 2019.
A conference call for investors will begin at 8:30 a.m. Eastern Time. The call can be accessed
in three ways:
- At the Mallinckrodt
website: http://www.mallinckrodt.com/investors.
- By telephone: For both listen-only participants and those who
wish to take part in the question-and-answer portion of the call,
the telephone dial-in number in the U.S. is (877) 359-9508. For
participants outside the U.S., the dial-in number is (224)
357-2393. Callers will need to provide the Conference ID of
6080969.
- Through an audio replay: A replay of the call will be available
beginning at 11:30 a.m. Eastern Time on
Tuesday, Nov. 5, 2019, and ending at 11:30 a.m. Eastern Time on Tuesday, Nov. 19,
2019. Dial-in numbers for U.S.-based participants are (855)
859-2056 or (800) 585-8367. Participants outside the U.S. should
use the replay dial-in number of (404) 537-3406. All callers will
be required to provide the Conference ID of 6080969.
ABOUT MALLINCKRODT
Mallinckrodt is a global business consisting of
multiple wholly owned subsidiaries that develop, manufacture,
market and distribute specialty pharmaceutical products and
therapies. The company's Specialty Brands reportable segment's
areas of focus include autoimmune and rare diseases in specialty
areas like neurology, rheumatology, nephrology, pulmonology and
ophthalmology; immunotherapy and neonatal respiratory critical care
therapies; analgesics and gastrointestinal products. Its Specialty
Generics reportable segment includes specialty generic drugs and
active pharmaceutical ingredients. To learn more about Mallinckrodt, visit www.mallinckrodt.com.
Mallinckrodt uses its website as a
channel of distribution of important company information, such as
press releases, investor presentations and other financial
information. It also uses its website to expedite public access to
time-critical information regarding the company in advance of or in
lieu of distributing a press release or a filing with the U.S.
Securities and Exchange Commission disclosing the same information.
Therefore, investors should look to the Investor Relations page of
the website for important and time-critical information. Visitors
to the website can also register to receive automatic e-mail and
other notifications alerting them when new information is made
available on the Investor Relations page of the website.
CONTACTS
Investor Relations
Daniel J. Speciale, CPA
Vice President, Investor Relations and IRO
314-654-3638
daniel.speciale@mnk.com
Media
Daniel Yunger
Kekst CNC
212-521-4879
mallinckrodt@kekstcnc.com
Mallinckrodt, the "M" brand mark and
the Mallinckrodt Pharmaceuticals logo are trademarks of a
Mallinckrodt company. © 2019
Mallinckrodt. 10/19
View original content to download
multimedia:http://www.prnewswire.com/news-releases/mallinckrodt-to-report-earnings-results-for-third-quarter-2019-300934682.html
SOURCE Mallinckrodt plc